Overview: TLE1 TestIntroduction: The TLE1 Test detects TLE1 expression to diagnose synovial sarcoma, causing joint pain or swelling. Following 2023 ASH guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected synovial sarcoma.
Other Names: TLE1 Assay, Synovial Sarcoma Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: TLE1 testing began in the 2000s with sarcoma research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects TLE1 expression to diagnose synovial sarcoma, guides treatment, and evaluates patients with joint pain or swelling.
Test Parameters: 1. TLE1 Expression
Pretest Condition: No fasting required. Collect serum or plasma. Report history of joint pain, swelling, or sarcoma symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document joint pain, swelling, or history of sarcomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, synovial sarcoma implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect TLE1 expression. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for sarcoma diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Non-specific TLE1 expression may reduce specificity.
Clinical Significance: Positive TLE1 expression confirms synovial sarcoma, guiding surgery or chemotherapy. Negative results may require biopsy or imaging.
Specialist Consultation: Consult an oncologist or orthopedic surgeon for result interpretation and treatment planning.
Additional Supporting Tests: Sarcoma biopsy, MRI, or FISH for SYT-SSX to confirm synovial sarcoma diagnosis.
Test Limitations: Non-specific for certain sarcomas; clinical correlation is needed. Sample quality affects sensitivity.
References: ASH Sarcoma Guidelines, 2023; Journal of Clinical Oncology, Ladanyi M, 2022.
